Single-center, open-label, randomized controlled trial comparing the tolerability of maribavir 400 mg twice daily versus standard-dose valganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients
Publication date: October 2026 Source: American Journal of Transplantation, Volume 26, Issue 10 Author(s): David J. Taber, Hannah Culpepper, Courtney E. Harris, Neha Patel, Morgan Overstreet, Felicia Bartlett, Sakshi Vaishnav, Maria Aurora Posadas Salas, Santosh Nagaraju, Steve Hanish
Single-center, open-label, randomized controlled trial comparing the tolerability of maribavir 400 mg twice daily versus standard-dose valganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients. // American Journal of Transplantation. – URL: https://www.sciencedirect.com/science/article/pii/S1600613526009962?dgcid=rss_sd_all
Single-center, open-label, randomized controlled trial comparing the tolerability of maribavir 400 mg twice daily versus standard-dose valganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients. American Journal of Transplantation. https://www.sciencedirect.com/science/article/pii/S1600613526009962?dgcid=rss_sd_all
“Single-center, open-label, randomized controlled trial comparing the tolerability of maribavir 400 mg twice daily versus standard-dose valganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients.” American Journal of Transplantation.
@article{article106676,
title = {Single-center, open-label, randomized controlled trial comparing the tolerability of maribavir 400 mg twice daily versus standard-dose valganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients},
journal = {American Journal of Transplantation},
url = {https://www.sciencedirect.com/science/article/pii/S1600613526009962?dgcid=rss_sd_all}
}